Jeffrey Zwicker, MD

Associate Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center

3 Blackfan Circle, Room 905, Boston MA 02215
Tel: 617-667-9299 FAX: 617-667-9922
jzwicker@bidmc.harvard.edu

Bio

Jeffrey Zwicker, M.D. is an Associate Professor of Medicine at Harvard Medical School and Chief of the Section of Benign Hematology at Beth Israel Deaconess Medical Center. Dr. Zwicker received a Bachelor of Science at University of California at Berkeley, Medical Degree at Penn State University and Masters of Medical Science at Harvard Medical School. He completed his residency and fellowship training at Beth Israel Deaconess Medical Center. Dr. Zwicker serves on national and international scientific committees including prior co-chair of the ISTH Subcommittee on Hemostasis and Cancer, Scientific Committee on Thrombosis and Vascular Biology at American Society of Hematology, and Nominating Committee at International Society of Thrombosis and Haemostasis, as well as on editorial boards for Journal of Thrombosis and Haemostasis and Research and Practice in Thrombosis and Haemostasis. Dr. Zwicker’s research is focused novel risk factors and therapeutic approaches to thrombotic disease with an emphasis on cancer associated thrombosis. He serves as the Director of Benign Hematology Research Group at BIDMC and is the primary investigator for several NIH funded clinical trials including: CATIQ (NCT02195232) which is a phase II/III trial evaluating the efficacy of isoquercetin to prevent thrombosis in cancer; a randomized, double-blind, phase II trial of weight adjusted versus standard dose enoxaparin in high risk hospitalized cancer patients (NCT0270629); and rosuvastatin with enoxaparin to prevent thrombosis and reduce tissue factor bearing microparticles following ovarian cancer surgery.

Dr. Zwicker’s research is focused on various aspects of cancer associated thrombosis. Current projects in the group include:

• Investigator-initiated clinical trials to prevent thrombosis:
  • In high risk cancer patients during hospitalization
  • In cancer outpatients using a novel inhibitor of protein disulfide isomerase
  • Following ovarian cancer surgery
• Understanding the risk and factors that influence intracranial hemorrhage in cancer patients receiving anticoagulation
• Investigating the molecular mechanisms of thrombosis in patients with myeloproliferative neoplasms
• Identifying novel biomarkers to predict thrombosis and hemorrhage in cancer patients